marijuana stocks

InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018 , which is the Company’s fourth quarter of fiscal year 2018 (“4Q18”), on Thursday, September 13, 2018 .

The Company’s full financial statements and related MD&A for the three and twelve months ended June 30, 2018 will be available at www.sedar.com on September 13, 2018 .

About InMed:
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

About Epidermolysis Bullosa (EB).  EB is a group of rare diseases that cause fragile, blistering skin.  The blisters may appear in response to minor injury, even from heat, rubbing, scratching or adhesive tape.  In severe cases, the blisters may occur inside the body, such as the lining of the mouth or the stomach.  Most types of epidermolysis bullosa are inherited.  The condition usually presents in infancy or early childhood.  Epidermolysis bullosa has no cure.

About INM-750.  INM-750 is a proprietary, topical cannabinoid product candidate targeted as a therapy in epidermolysis bullosa (EB) and other potential dermatological and wound-healing applications. It has been specifically designed with the intent to: (i) modify the underlying cause of the disease in certain patients with EB Simplex (EBS, the most common form of EB), and (ii) to treat the major symptoms of the disease in all patients with EB. Preclinical data generated previously demonstrates that INM-750 may have a significant impact on certain symptoms of EB (which may include improvement of wound area to promote healing, reduction in pain, itch and inflammation, and providing antimicrobial activity). These disease hallmarks are key therapeutic targets for the effective treatment of EB as well as several other dermatological conditions. Additionally, our data indicate that INM-750 may have an impact on the underlying disease by increasing the production of certain proteins, called keratins, in the skin.

About Glaucoma.  Glaucoma is a group of eye conditions that damage the optic nerve, which is vital to good vision.  This damage is often caused by an abnormally high pressure in your eye.  It is the second leading cause of blindness worldwide.  It can occur at any age but is more common in older adults.  The most common form of glaucoma has no warning signs.  The effect is so gradual that you may not notice a change in vision until the condition is at an advanced stage.  Vision loss due to glaucoma can’t be recovered.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published.

You May Also Like

$TRTC Grand Opening Date of Second Nevada-Based Medical Cannabis Dispensary

Terra Tech Announces Grand Opening Date of Second Nevada-Based Medical Cannabis Dispensary…

11/30/2017: Ready For This?

This Connect The Dots Company Just Got REAL! (CRPGF) X-SPRAYS Announces Exclusive…

Koios Beverage Corp. (KBEVF) Now Available in an Additional 210 GNC Franchise Locations

Koios Beverages Now Available in an Additional 210 GNC Franchise Locations Koios…

Canopy Growth Corporation (CGC) and TerrAscend Canada Enter Debt Financing Arrangement

Canopy Growth and TerrAscend Canada Enter Debt Financing Arrangement Canopy Growth Corporation…